Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance (NCT01463670), a na phase 2 study. The primary outcome is Overall Response Rate (ORR).

2. Clinical Question

The rationale recorded for the trial is that it was uncertain whether disease progressing during low-dose maintenance would respond to higher-dose lenalidomide. The study was intended to examine effects on both patients and disease. The registry record describes this as a phase II investigation; it does not establish a comparative treatment effect.

3. Trial Design

The registry identifies NCT01463670 as a completed phase II clinical trial sponsored by Memorial Sloan Kettering Cancer Center. The recorded start date is 2011-10-28, and the primary completion date is 2021-03-19. Enrollment is listed as 11. The registered model is single group, allocation is not applicable, and masking is none. These design details indicate that the study was not registered as a randomized comparison and did not include a blinded treatment assignment.

The intervention was lenalidomide intensification in patients with multiple myeloma experiencing serologic or asymptomatic progression while taking lenalidomide maintenance. The arm description characterizes the proposed study as multi-center and refers to patients receiving low-dose maintenance after high-dose melphalan and autologous stem cell transplant, or continuous or maintenance therapy following initial treatment. The registry record does not report how many centers enrolled participants or provide the actual treatment dose and schedule.

The primary outcome was overall response rate, with a timeframe of 6 months. The record says 10 participants were evaluable for the primary response endpoint. Enrollment and endpoint evaluability are distinct entries in the registry; the reason for the difference and the handling of participants without an evaluable response are not reported. A secondary outcome is the number of participants evaluated for toxicity.

The registry lists two outcome measures, but does not report a primary response count or describe a statistical analysis for that endpoint. It records zero analyses. The protocol’s statistical analysis plan, any prespecified analysis populations beyond the stated evaluable population, and any interim analysis procedures are not reported in the registry record. The single-group structure is important when interpreting the findings: any observed outcome would describe participants treated in this study, without a concurrent randomized group to distinguish treatment-associated change from other influences.

Planning illustrations use assumptions described as a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Those assumptions are not a description of this single-group trial’s registered allocation. The illustrations are planning scenarios, not observed power, and their calculated values are not reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Analysis population for the primary outcome, as defined in the registry: A total of 10 patients were evaluable for the primary endpoint of response.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Overall Response Rate (ORR), measured over 6 months.

The primary endpoint is overall response rate, abbreviated ORR, at 6 months. It is intended to classify whether participants meet criteria for a complete or partial response. The registry defines complete response as disappearance of all target lesions. It defines partial response as at least a 30% decrease in the sum of the longest diameter of target lesions. Overall response is defined as complete response plus partial response. The assessment is described as using RECIST v1.0 criteria for target lesions and MRI.

Response endpoints are used in clinical trials to summarize whether disease measurements meet prespecified criteria for improvement. A categorical endpoint such as ORR turns lesion assessments into response classifications, which can be summarized across an evaluable population. The classification depends on the criteria and assessment method specified for the study; it does not by itself describe how long a response lasts or provide a comparison with an untreated or differently treated group.

For this trial, the registry identifies 10 participants as evaluable for the primary endpoint, but does not report the number meeting complete-response or partial-response criteria. It also does not report an ORR estimate, confidence interval, or hypothesis test. Consequently, the endpoint definition and timeframe are available, but the posted registry information does not establish the observed response rate or its precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation depends on connecting the design, endpoint definition, analysis population, and reported result. In this trial, the registry describes a single-group phase II design and identifies ORR at 6 months as the primary endpoint. It does not report the primary response count, an estimate, an uncertainty interval, or an analysis result. The endpoint can therefore be explained, but the response analysis itself cannot be reconstructed from the registry record.

What does a single-group design estimate?

A single-group study observes outcomes among participants receiving the study intervention. It can describe the outcomes recorded in that group, subject to the endpoint definition and population analyzed. It does not supply a concurrent comparison group. Without such a comparator, a difference between outcomes under intensification and outcomes under another strategy cannot be estimated directly from this design. This limits causal interpretation even if an outcome is observed.

Here, the registered model is single group, allocation is not applicable, and masking is none. There is no registered randomized treatment allocation to balance measured or unmeasured participant characteristics between intervention groups. The record does not describe a control arm. Thus, any reported response would be an outcome in the treated group rather than a randomized comparative estimate.

How is the primary endpoint defined?

ORR is the combined category of complete response and partial response. The registry states that complete response means disappearance of all target lesions. Partial response requires at least a 30% decrease in the sum of the longest diameter of target lesions. The listed assessment uses MRI and RECIST v1.0 criteria for target lesions. These definitions specify how the response categories are intended to be determined. They do not reveal how many participants met either category.

A response rate is ordinarily a proportion: the number meeting the response definition relative to the analysis population. That general description does not permit a rate to be calculated in this case, because the number of responders is not reported. The record identifies 10 participants as evaluable, but does not give the complete-response count, partial-response count, or combined response count. No rate should be inferred from enrollment or safety counts.

What does an uncertainty interval contribute?

General statistical explanation: an uncertainty interval, such as a confidence interval, communicates how imprecisely an estimate is determined by the observed data and the chosen method. A narrow interval indicates greater precision than a wide interval, all else being comparable. An interval does not remove limitations in study design, and it cannot correct for the lack of a concurrent comparator. No response confidence interval is reported in the registry record, so the precision of the primary endpoint cannot be assessed from the posted results.

What are the planning illustrations?

The planning assumptions describe a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. They say that the effect to detect is a stated fraction of the observed effect. For time-to-event outcomes, the described planning quantity is the total number of events; for other outcomes it is participants per arm. These are planning conventions, not observations from the clinical trial. In particular, the two-arm equal-allocation assumption does not match the registered single-group structure. The planning illustrations are not observed power. Their calculated values and the effect fractions are not reported in the registry record.

General statistical explanation: a planning calculation estimates the amount of information a future study might need under assumptions about the effect, error rate, allocation, and analysis method. Its result is conditional on those assumptions. It does not show that a completed study had a particular probability of detecting an effect after its results are known. Because the underlying planning outputs are not reported in the registry record, no sample-size requirement or effect magnitude can be stated for this trial.

Why can event counts be difficult to interpret?

General statistical explanation: event counts may be more variable than a simple model assumes, especially when participants differ in their underlying event propensity or when observations cluster. Over-dispersion means that variation exceeds what a chosen probability model expects; ignoring it can make uncertainty appear too small. This is a general issue in count-data analysis, not a reported finding about this trial. The registry record does not describe a count model, an over-dispersion adjustment, or a statistical analysis of the safety counts.

The primary endpoint is categorical rather than a count of repeated events: participants are classified as complete responders, partial responders, or not meeting the combined response definition. The record does not report inferential methods for that endpoint. It also does not state whether any adjusted analysis was planned. These methods cannot be reconstructed from the trial’s phase designation or from the endpoint definition alone.

What can be concluded from the statistical record?

The available entries identify the design, endpoint, timeframe, and stated evaluable population. They do not provide the outcome information required to estimate ORR or its precision. The registry also records zero analyses, but does not explain whether that reflects absent analysis information, no posted analysis records, or another registry convention. A statistical conclusion about the efficacy endpoint would therefore go beyond what is reported. The appropriate reading is to distinguish the defined question from the unreported answer.

10. Multiplicity, Missing Data and Analysis Populations

The registry identifies ORR at 6 months as the primary outcome and lists the number of participants evaluated for toxicity as a secondary outcome. It also records two outcome measures and zero analyses. The record does not describe a multiplicity adjustment, a hierarchy among outcomes, or a plan for controlling the chance of false-positive findings when examining multiple outcomes. It is therefore not possible to determine from the registry record whether or how multiplicity was addressed.

The primary response population is described as 10 evaluable participants, while enrollment is listed as 11. The record does not explain why these counts differ, identify the response status of participants who were not evaluable, or state how missing outcome data were handled. It does not specify whether response analyses used an intention-to-treat approach, an evaluable-population approach beyond the stated count, or another analysis population. No imputation method or sensitivity analysis for missing response data is reported.

These omissions affect interpretation in different ways. The absence of a multiplicity plan leaves uncertainty about how multiple outcomes or analyses were considered statistically. The absence of missing-data methods leaves uncertainty about how the primary endpoint would be summarized if a participant’s response assessment were unavailable. Neither issue can be resolved by the enrollment count alone.

The record does not report the primary response count or an analysis result. Accordingly, no claim about statistical significance, adjusted significance, or robustness to missing data can be made from the posted results. The listed safety counts are descriptive registry entries; the analysis population and inferential method for those counts are not reported.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Serious events with the highest arm-level rate: lung infection (18.2%), thromboembolic event (18.2%), atelectasis (9.1%), atrial fibrillation (9.1%), blurred vision (9.1%).

The registry lists one lenalidomide group. For serious adverse events, 11 participants are recorded as at risk and 6 as affected. For other adverse events, 11 are listed as at risk and 0 as affected. The registry also records 6 deaths. These are the posted counts; the record does not provide the timing or causes of death or establish that deaths were related to treatment.

The serious adverse event terms listed with percentages are lung infection, 18.2%; thromboembolic event, 18.2%; atelectasis, 9.1%; atrial fibrillation, 9.1%; blurred vision, 9.1%; and dyspnea, 9.1%. These entries identify reported terms and their associated percentages. The registry record does not explain the event-level counting rules, whether participants could contribute more than one term, or the denominator used for each listed percentage. They should not be treated as mutually exclusive categories or added together.

Safety counts describe events recorded in the study; by themselves they do not establish causation. The record does not report a comparison group that would support a comparative safety estimate. It also does not provide contextual detail about severity beyond the serious-event classification, duration, treatment relationship, or outcomes of the listed events. The serious-event, other-event, and death entries should therefore be read as separate registry summaries, not as evidence that lenalidomide caused any particular event or death.

12. What the Result Does, and Does Not, Mean

The trial is relevant to a specific clinical research question: whether response was observed after lenalidomide was intensified in patients with multiple myeloma progressing during lenalidomide maintenance. The registry defines the intervention and a response endpoint at 6 months. It also reports that 10 participants were evaluable for that endpoint. These details establish what the study set out to assess, but they do not supply the primary response result.

The most important distinction is between an endpoint definition and an endpoint finding. The record explains the response categories and assessment criteria, but does not report how many participants achieved complete or partial response. It therefore does not support a conclusion about the observed ORR, the precision of that rate, or whether an analysis met any statistical threshold. The absence of a posted response count should not be interpreted as a count of zero.

The single-group design also limits the meaning of any within-study response. Without a concurrent control group, a response observed after intensification would not by itself establish what would have happened under another treatment strategy. The registry record does not support a randomized comparison or a causal estimate of treatment effect.

The safety entries should be interpreted on their own terms. The record lists serious adverse events, other adverse events, serious-event terms with percentages, and deaths. It does not establish event causality or explain death timing and causes. These entries do not fill the gap in the unreported primary efficacy result, and they do not allow a comparative safety conclusion.

Thus, the record supports a description of the study design, registered question, and posted safety counts. It does not support a judgment that lenalidomide intensification did or did not produce a particular response outcome. Additional outcome and analysis information would be needed to characterize the observed response and its uncertainty. No treatment recommendation follows from the registry information alone.

13. Why This Trial Matters Statistically

This study is statistically notable because its clinical question concerns treatment intensification after progression during maintenance with the same drug. That creates an understandable question about whether response can still be observed, while also making the design and endpoint reporting especially important. The registry identifies the intended response measure and the population considered evaluable, but does not post the response count needed to answer the question quantitatively.

The single-group structure provides a clear descriptive frame but not a randomized contrast. Researchers and readers can distinguish what happened among treated participants from what a comparative design would estimate. In the absence of a control arm, outcomes cannot isolate an effect attributable to intensification. This limitation is not repaired by naming the study phase or by having a defined response criterion.

The difference between enrollment and endpoint evaluability also highlights why analysis populations and missing-data procedures matter. The registry lists 11 enrolled participants and 10 evaluable for response, but does not explain the difference. Without that explanation, readers cannot assess how exclusions or unavailable response assessments might affect the endpoint summary.

The posted safety counts add a separate descriptive dimension, but not a causal comparison. Serious adverse events, other adverse events, and deaths are listed without enough context to establish their relationship to the intervention. Taken together, the record illustrates a broad statistical lesson: a well-defined research question and endpoint are not substitutes for a reported estimate, uncertainty measure, and transparent account of the population analyzed.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpretation is that the registry record does not report the primary ORR result. It gives the endpoint definition, 6-month timeframe, and the statement that 10 participants were evaluable, but not the number with complete response, partial response, or overall response. No estimate, confidence interval, or primary analysis result is reported. The efficacy question therefore remains unanswered by the posted results.

The study is registered as single group, with allocation not applicable and no masking. There is no randomized comparator in the design, so comparative treatment effects cannot be estimated from the study structure. The arm description refers to a proposed multi-center trial, but the record does not state how many centers contributed participants. Treatment dose, schedule, duration, and modification procedures are also not reported.

Enrollment is listed as 11 and the primary endpoint population as 10 evaluable participants. The reason for this difference, the response status of anyone not evaluable, and the missing-data approach are not reported in the registry record. The record does not describe an intention-to-treat analysis or sensitivity analyses.

The record names a secondary toxicity outcome but does not provide a statistical analysis plan or multiplicity approach. It records zero analyses, without further explanation. Safety entries include event counts and listed serious-event percentages, but do not state the event-counting rules or clarify the denominator for each percentage. Causes and timing of the recorded deaths are not reported, and causality is not established.

Finally, the planning assumptions describe a two-arm equal-allocation framework, whereas the registered trial is single group. The planning illustrations are not observed power, and their calculated values are not reported in the registry record. These limitations constrain both efficacy and safety interpretation.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Lenalidomide Intensification in Patients With Serologic/Asymptomatic Progression of Multiple Myeloma While on Lenalidomide Maintenance — NCT01463670.
• Registry record last updated 2022-05-06; status last verified 2021-03.
• Results first posted 2022-05-06.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01463670 is a completed phase II, single-group study sponsored by Memorial Sloan Kettering Cancer Center. The registry lists 11 enrolled participants and describes lenalidomide intensification for multiple myeloma progressing during lenalidomide maintenance. Allocation is not applicable and masking is none.

The primary outcome is ORR at 6 months, using complete and partial response criteria based on RECIST v1.0 target-lesion assessment by MRI. The record states that 10 participants were evaluable for the primary endpoint, but does not report the response count or rate. The reason for the difference between enrollment and evaluability is not reported.

Safety entries list 6 participants with serious adverse events, 0 with other adverse events, and 6 deaths. The record does not establish causation or report death causes and timing. It lists a toxicity outcome but no statistical analyses. The posted information describes the trial question and design, while leaving the primary response result and important analysis details unreported.